NeuroOne Secures First Pharmaceutical Industry Purchase Order For StereoCED Drug Delivery Platform; No Terms Disclosed

Major Commercial Milestone Represents Important Step Toward Potential Long-Term Collaborations with Global Pharmaceutical Companies

EDEN PRAIRIE, Minn., Oct. 22, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced that it has secured its first pharmaceutical industry purchase order for the StereoCED™ Drug Delivery Platform to support a preclinical animal research program for a Tier 1 global pharmaceutical company.

The research program is expected to commence in large animals early next year. The study will leverage StereoCED's unique combination of targeted intracranial drug delivery and electrophysiological recording capabilities, which the Company believes is the only integrated platform of its kind. Unlike other leading drug delivery devices that are not intended for implantation, StereoCED™ is designed to support extended implantation of the electrode for less than 30 days, enabling longitudinal neurological EEG monitoring before and after drug administration. This capability could provide valuable insights into the therapeutic agent’s biological activity and efficacy over time.

This first pharmaceutical industry purchase order represents a significant commercial milestone for NeuroOne and an important step in its strategy to establish StereoCED™ as a preferred drug delivery platform for the global pharmaceutical industry. By engaging with pharmaceutical partners early in therapeutic development, NeuroOne aims to establish its technology as an integral part of the drug development process. As programs advance from preclinical research through human clinical trials and potentially commercialization, continuity with an established delivery platform may reduce development complexity and create opportunities for long-term partnerships and recurring revenue.